阿达木单抗药物监测及对非感染性葡萄膜炎中药物抗体者的治疗调整
该回顾性病例系列在42例接受阿达木单抗治疗的非感染性葡萄膜炎患者中,于起始后17.9个月检测阿达木单抗及抗阿达木单抗抗体(AAA)。22例(52.4%)无应答者检出AAA,其平均阿达木单抗谷浓度显著低于无AAA者。增加阿达木单抗剂量并加用低剂量cDMARD者AAA下降幅度最大。
要点
- 42例非感染性葡萄膜炎患者中,22例(52.4%)无应答者检出AAA。
- AAA阳性者平均阿达木单抗谷浓度3.0 µg/mL,显著低于无AAA者的11.8 µg/mL。
- 增加阿达木单抗剂量并加用免疫抑制剂者AAA下降幅度最大(-3565 ng/mL)。
核心结论
- 无应答患者中88%检出AAA,且与阿达木单抗药物浓度检测不到相关,提示免疫原性是生物治疗葡萄膜炎患者失去应答的主要原因。
- 对药物浓度低的免疫化无应答者,增加阿达木单抗注射剂量并加用低剂量cDMARD是最有效的调整。
研究设计与样本
- 回顾性病例系列;单中心研究,纳入接受阿达木单抗治疗的非感染性葡萄膜炎患者,采集血样检测阿达木单抗及AAA,并分析无应答者监测后的治疗调整。
主要发现
- 42例患者在阿达木单抗起始后17.9个月接受实验室检查,其中22例(52.4%)无应答者检出AAA(1243 ng/mL),平均阿达木单抗谷浓度为3.0 µg/mL,显著低于无AAA患者的平均药物浓度11.8 µg/mL。
- 15例(35.7%)患者同时接受第二种免疫抑制剂治疗,但其平均抗体水平和平均阿达木单抗水平与单药治疗组相比无统计学显著差异(P = .13和P = .34)。
- 在无应答者中,增加阿达木单抗剂量并加用另一种免疫抑制剂者AAA下降和复发管理效果最大(-3565 ng/mL),其次为换用另一种生物制剂者(-1153 µg/mL)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To explore the incidence of antibodies against adalimumab (AAA) development in noninfectious uveitis (NIU) and to examine the impact of treatment adjustment in nonresponders. DESIGN: Retrospective case series. METHODS: In this single-center study of patients with NIU treated with adalimumab, blood samples for adalimumab and AAA were collected and therapeutic adjustments post-monitoring in non-responders were analyzed including changes in injection intervals, addition of conventional disease-modifying antirheumatic drugs (cDMARD), and treatment alterations to biologic DMARD. The main outcome measures were the proportion of patients with positive AAA and active uveitis, decrease of AAA at final follow-up by different therapeutic interventions. RESULTS: Of 42 patients who underwent laboratory investigations at 17.9 months after adalimumab initiation, 22 (52.4%) patients who were nonresponders demonstrated AAA (1243 ng/mL) with a mean adalimumab trough level of 3.0 µg/mL, significantly lower than the mean drug levels of patients without AAA (11.8 µg/mL). Fifteen (35.7%) patients were receiving concurrent treatment with a second immunosuppressive agent, but the mean antibody level and the mean adalimumab level were not statistically significantly different from the monotherapy group (P = .13 and P = .34). Reduction in AAA levels and relapse management was greatest among nonresponders who were treated by increasing the adalimumab dose and adding an additional immunosuppressive drug (-3565 ng/mL), followed by patients who were shifted to a different biologic (-1153 ug/mL). CONCLUSIONS: The presence of AAA was detected in 88% of nonresponder patients and was associated with undetectable adalimumab drug levels. This underscores immunogenicity as a major cause of loss of response in uveitis patients receiving biotherapies. Increasing the dose of adalimumab injections together with the addition of low-dose cDMARDs was the most effective adjustment in immunized nonresponders for whom the adalimumab drug concentration was low.
引用
- Pichi F, Smith SD, AlAli SH, et al. Adalimumab Drug Monitoring and Treatment Adjustment to Drug Antibodies in Noninfectious Uveitis. Am J Ophthalmol. 2024. PMID: 39271091. doi:10.1016/j.ajo.2024.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。